English  |  正體中文  |  简体中文  |  Items with full text/Total items : 16984/19280 (88%)
Visitors : 8467323      Online Users : 452
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.cnu.edu.tw/handle/310902800/32207


    標題: In vitro and in vivo antibacterial activity of tigecycline against Vibrio vulnificus
    作者: Tang, Hung-Jen
    Chen, Chi-Chung
    Lai, Chih-Cheng
    Zhang, Chun-Cheng
    Weng, Tzu-Chieh
    Chiu, Yu-Hsin
    Toh, Han-Siong
    Chiang, Shyh-Ren
    Yu, Wen-Liang
    Ko, Wen-Chien
    Chuang, Yin-Ching
    貢獻者: Chi Mei Med Ctr, Dept Med
    Chia Nan Univ Pharm & Sci, Dept Hlth & Nutr
    Chi Mei Med Ctr, Dept Med Res
    Chi Mei Med Ctr, Dept Intens Care Med
    Chi Mei Med Ctr, Dept Med
    Natl Cheng Kung Univ, Med Coll & Hosp, Dept Med
    關鍵字: killing effects
    tigecycline
    Vibrio vulnificus
    日期: 2018-02
    上傳時間: 2019-11-15 15:45:12 (UTC+8)
    出版者: ELSEVIER TAIWAN
    摘要: Background/purpose: The aim of this study is to investigate the role of tigecycline in Vibrio vulnificus infection. Methods: Eight randomly selected clinical V. vulnificus isolates were studied to obtain the minimal inhibitory concentrations (MICs) of minocycline, cefotaxime, and tigecycline, and the timeekill curves of tigecycline alone or in combination with other drugs. A peritonitis mouse model was used for the evaluation of the therapeutic efficacy of tigecycline alone or cefotaxime in combination with minocycline or tigecycline. Results: The MIC of minocycline, cefotaxime, and tigecycline for eight clinical V. vulnificus isolates was 0.06-0.12 mu g/mL, 0.03-0.06 mu g/mL, and 0.03-0.06 mu g/mL, respectively. In time ekilling studies, at the concentration of 1 x MIC, the inhibitory effect of tigecycline persisted for 24 hours in five of eight isolates. With 2 x MIC and trough level, the inhibitory effect was noted in all isolates for 24 hours. With the combination of minocycline plus cefotaxime and tigecycline plus cefotaxime at 1/2 x MIC, the bactericidal effect was noted in 25% and 62.5% of eight isolates and synergism in 50% and 75% of isolates. With a low (1.25 x 10(5) CFU/mL) inoculum, all infected mice survived with tigecycline alone, tigecycline plus cefotaxime, or minocycline plus cefotaxime on the 14th day. At the inoculum of 1.25 x 10(6) CFU, the survival rate was 33.3% on the 14th day in the tigecycline plus cefotaxime-treated group, but none of the mice treated by tigecycline alone or minocycline plus cefotaxime survived (33.3% vs. 0%, p = 0.01 by Fisher's exact test). Conclusion: Our in vitro combination and animal studies indicate that tigecycline could be an option for the treatment of invasive V. vulnificus infections. Copyright (C) 2016, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC.
    link: http://dx.doi.org/10.1016/j.jmii.2016.04.009
    Appears in Collections:[保健營養系(所) ] 期刊論文

    Files in This Item:

    File Description SizeFormat
    10.1016-j.jmii.2016.04.009.pdf377KbAdobe PDF7View/Open
    index.html0KbHTML19View/Open


    All items in CNU IR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback